Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial

NCT07407920 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

120

Enrollment

OTHER

Sponsor class

Conditions

Anatomic Stage I Breast Cancer AJCC v8
Anatomic Stage II Breast Cancer AJCC v8
Early Stage HER2-Positive Breast Carcinoma
Early Stage Triple-Negative Breast Carcinoma

Interventions

PROCEDURE: Biospecimen Collection
DRUG: Hormone Therapy
BIOLOGICAL: Pembrolizumab
BIOLOGICAL: Pertuzumab
BIOLOGICAL: Trastuzumab

Sponsor

M.D. Anderson Cancer Center